Recently, our company has reached a strategic cooperation with Boya united pharmaceutical institute CO.,LTD. on the Toutongding Syrup (100ml/bottle), to obtain the exclusive agency of the product.
MoreThe environmentally friendly R&D center in Pudong, Shanghai, covering a floor area of more than 2,400 m2, will focus on the development of innovative drugs such as anti-infective, anti-diabetic, anti-tumor, anti-obesity, and peptide drugs.
MoreC&O is committed to the pursuit of the highest quality, and superior production capabilities, Nanjing Chang Ao Pharmaceutical Co., Limited was awarded the title of “technology-intensive and knowledge-intensive enterprise” by the Department of Science
MoreIn April 2008, a wholly-owned subsidiary of C&O - Shenzhen Liancheng Medicine Company Limited - entered into an acquisition agreement with Nanjing Xinaokang Pharmaceutical Limited to acquire 100% equity interest in the latter for 40 million yuan in c
MoreIn March 2008, Chang Ao Investment Limited (BVI), a wholly-owned subsidiary of C&O, entered into a joint venture agreement with XenoBiotic Labs (“XBL”), a leading U.S. contract research services provider, to establish a research laboratory in Nanjing
More
Address5/F, Jihao Building, 1086 Shennan East Road, Luohu District, Shenzhen
Adverse drug reactions / Event feedback hotline025-6816 1304
Adverse drug reactions / Event feedback mail[email protected]
Official WeChat account Mobile page